<?xml version='1.0' encoding='utf-8'?>
<document id="31257298"><sentence text="Involvement of Renal Efflux Transporter MATE1 in Renal Excretion of Flecainide."><entity charOffset="68-78" id="DDI-PubMed.31257298.s1.e0" text="Flecainide" /></sentence><sentence text="Flecainide, an anti-arrhythmic drug, undergoes renal excretion through active renal tubular secretion in addition to passive glomerular filtration"><entity charOffset="0-10" id="DDI-PubMed.31257298.s2.e0" text="Flecainide" /></sentence><sentence text=" The contribution of renal uptake and efflux transporters in active renal tubular secretion of flecainide remains unclear except that flecainide is a substrate of human multidrug resistance protein 1 (MDR1)"><entity charOffset="95-105" id="DDI-PubMed.31257298.s3.e0" text="flecainide" /><entity charOffset="134-144" id="DDI-PubMed.31257298.s3.e1" text="flecainide" /><pair ddi="false" e1="DDI-PubMed.31257298.s3.e0" e2="DDI-PubMed.31257298.s3.e0" /><pair ddi="false" e1="DDI-PubMed.31257298.s3.e0" e2="DDI-PubMed.31257298.s3.e1" /></sentence><sentence text=" To elucidate renal efflux and uptake transporters involved with active renal tubular secretion of flecainide, we conducted in vitro interaction studies of flecainide using organic cation transporter 2 (OCT2), multidrug and toxin extrusion (MATE) 1, and MATE2-K"><entity charOffset="99-109" id="DDI-PubMed.31257298.s4.e0" text="flecainide" /><entity charOffset="156-166" id="DDI-PubMed.31257298.s4.e1" text="flecainide" /><pair ddi="false" e1="DDI-PubMed.31257298.s4.e0" e2="DDI-PubMed.31257298.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31257298.s4.e0" e2="DDI-PubMed.31257298.s4.e1" /></sentence><sentence text=" Uptake transporter inhibition assays using hOCT2-Chinese hamster ovary (CHO), hMATE1-CHO, and hMATE2-K-Madin Darby canine kidney strain II (MDCKII) cells revealed that flecainide (2"><entity charOffset="79-89" id="DDI-PubMed.31257298.s5.e0" text="hMATE1-CHO" /><entity charOffset="169-179" id="DDI-PubMed.31257298.s5.e1" text="flecainide" /><pair ddi="false" e1="DDI-PubMed.31257298.s5.e0" e2="DDI-PubMed.31257298.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31257298.s5.e0" e2="DDI-PubMed.31257298.s5.e1" /></sentence><sentence text="5 µM) inhibited hMATE1-mediated transport by 40% with an IC50 value of 6" /><sentence text="7 µM; however, it showed no or weak inhibitory effects on hOCT2- and hMATE2-K-mediated transport" /><sentence text=" For investigating flecainide as a substrate of hMATE1, the accumulation of flecainide in hMATE1-CHO was compared with that in control cells"><entity charOffset="19-29" id="DDI-PubMed.31257298.s8.e0" text="flecainide" /><entity charOffset="76-86" id="DDI-PubMed.31257298.s8.e1" text="flecainide" /><entity charOffset="90-100" id="DDI-PubMed.31257298.s8.e2" text="hMATE1-CHO" /><pair ddi="false" e1="DDI-PubMed.31257298.s8.e0" e2="DDI-PubMed.31257298.s8.e0" /><pair ddi="false" e1="DDI-PubMed.31257298.s8.e0" e2="DDI-PubMed.31257298.s8.e1" /><pair ddi="false" e1="DDI-PubMed.31257298.s8.e0" e2="DDI-PubMed.31257298.s8.e2" /><pair ddi="false" e1="DDI-PubMed.31257298.s8.e1" e2="DDI-PubMed.31257298.s8.e1" /><pair ddi="false" e1="DDI-PubMed.31257298.s8.e1" e2="DDI-PubMed.31257298.s8.e2" /></sentence><sentence text=" Uptake transporter substrate assay revealed that flecainide (1 µM) showed 1"><entity charOffset="50-60" id="DDI-PubMed.31257298.s9.e0" text="flecainide" /></sentence><sentence text="11-fold accumulation though the hMATE1-related active transport was significantly decreased in the presence of quinidine (42"><entity charOffset="111-120" id="DDI-PubMed.31257298.s10.e0" text="quinidine" /></sentence><sentence text="0 ± 23" /><sentence text="9 vs" /><sentence text=" 11" /><sentence text="8 ± 4" /><sentence text="1 pmol/mg in transfected cells; p &lt; 0" /><sentence text="05)" /><sentence text=" These results suggest that flecainide is a weak substrate of hMATE1, which is involved in the renal tubular secretion of cationic drugs, and hMATE1 may be less important in the pharmacokinetic drug-drug interaction for renal excretion of flecainide"><entity charOffset="28-38" id="DDI-PubMed.31257298.s17.e0" text="flecainide" /><entity charOffset="239-249" id="DDI-PubMed.31257298.s17.e1" text="flecainide" /><pair ddi="false" e1="DDI-PubMed.31257298.s17.e0" e2="DDI-PubMed.31257298.s17.e0" /><pair ddi="false" e1="DDI-PubMed.31257298.s17.e0" e2="DDI-PubMed.31257298.s17.e1" /></sentence><sentence text=" However, in vivo drug-drug interaction studies of flecainide with substrates of hMATE1 may be needed because flecainide has the potential to inhibit hMATE1"><entity charOffset="51-61" id="DDI-PubMed.31257298.s18.e0" text="flecainide" /><entity charOffset="110-120" id="DDI-PubMed.31257298.s18.e1" text="flecainide" /><pair ddi="false" e1="DDI-PubMed.31257298.s18.e0" e2="DDI-PubMed.31257298.s18.e0" /><pair ddi="false" e1="DDI-PubMed.31257298.s18.e0" e2="DDI-PubMed.31257298.s18.e1" /></sentence><sentence text="" /></document>